{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-087031","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.204965+00:00","generated_at":"2026-05-31T11:03:36.109192+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Edgewise Therapeutics Q2 2024 net loss $31.5M; cash $511.8M; EDG-7500 Phase 1 complete","bullets":["Net loss of $31.5M ($0.34 per share) vs $28.5M in prior quarter; no product revenue.","Cash and marketable securities $511.8M as of June 30, 2024.","Completed Phase 1 SAD/MAD trial of EDG-7500 in healthy volunteers; Phase 2 CIRRUS-HCM enrolling.","Sevasemten: CANYON Phase 2 data in Becker expected Q4 2024; GRAND CANYON pivotal cohort ongoing.","LYNX Phase 2 in Duchenne data expected Q4 2024; Phase 3 planned H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-087031","json":"https://secwatch.observer/filing/0001104659-24-087031.json","markdown":"https://secwatch.observer/filing/0001104659-24-087031.md","text":"https://secwatch.observer/filing/0001104659-24-087031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924087031/0001104659-24-087031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924087031/tm2420690d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:03:36.109192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}